Atkins Michael B - Georgetown Lombardi Comprehensive Cancer Center, Georgetown University

基本信息

浏览量：40

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 193 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Yili Zhang,Shaked Lev-Ari,Neil J. Shah,Samir Gupta,Jacob Peter Zaemes,Adil Alaoui,Peter McGarvey,Michael B. Atkins

Journal of Clinical Oncologyno. 16_suppl (2024): e14650-e14650

引用0浏览0引用

615 the Impact of Gender Including Female Menopausal Status on the Safety and Efficacy of Immune Checkpoint Inhibitors

Michael B Atkins,Neil J Shah,Jacob Zaemes,Andrew Pecora, Shaked Lev Ari,Lauren Pascual,Brittany Sinclaire,Alexandra DellaPia,Rachel A Zemel,Adil Alaoui,Andrew Ip, Deniz Ozisik,Ming Tan

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

A Phase II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Entinostat in Combination with Nivolumab Plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab Plus Ipilimumab or Nivolumab Alone

Roberto Pili,Nabil Adra,Theodore F. Logan,Heather Burney,Michael B. Atkins

JOURNAL OF CLINICAL ONCOLOGY (2023)

引用0浏览0引用

Treatment-free Survival (TFS) Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (arcc) (HCRN GU16-260-Cohort A)

Michael B. Atkins,Opeyemi Jegede,David F. McDermott,Naomi B. Haas,Mehmet Asim Bilen,Mark N. Stein,Jeffrey A. Sosman,Elizabeth R. Plimack,Robert S. Alter,Moshe Chaim Ornstein,Michael E. Hurwitz,David J. Peace,David Johnson Einstein,Paul J. Catalano,Hans J. Hammers,Meredith M. Regan

Journal of Clinical Oncologyno. 6_suppl (2023): 604-604

引用2浏览0引用

Extended Follow-Up from JAVELIN Renal 101: Subgroup Analysis of Avelumab Plus Axitinib Versus Sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium Risk Group in Patients with Advanced Renal Cell Carcinoma

J. B. A. G. Haanen,J. Larkin,T. K. Choueiri,L. Albiges,B. I. Rini,M. B. Atkins,M. Schmidinger,K. Penkov, E. Michelon,J. Wang,M. Mariani,A. di Pietro,R. J. Motzer

ESMO OPEN（2023）

引用29浏览0WOS引用

1317 Enhancing Patient Safety in Melanoma Treatment: Harnessing Machine Learning for Predicting Immune-Related Adverse Events

Samir Gupta,Michael B Atkins,Neil J Shah,Jacob Zaemes, Shaked Lev Ari, Yili Zhang,Adil Alaoui,Subha Madhavan,Peter McGarvey

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Interim Analysis of a Phase II Study of Nivolumab/ipilimumab Plus Cabozantinib in Patients with Unresectable Advanced Melanoma

Geoffrey Thomas Gibney,Andrew L. Pecora,Suthee Rapisuwon,Kevin Chen,Kellie Gardner, Gayle Cramer, Danielle Blair, Amy Avergas,Nicole Swanson,Jaeil Ahn,Michael B. Atkins

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用1浏览0引用

1892P A Pooled Meta-Analysis of Salvage Nivolumab/ipilimumab (N+I) after Nivolumab (N) in Patients with Advanced Renal Cell Carcinoma (RCC)

R. R. Mckay,W. Xie,K. Leucht,O. Jegede,D. A. Braun,M. B. Atkins,M-O. Grimm,T. K. Choueiri

Annals of Oncology (2023): S1017-S1018

引用0浏览0引用

Update on the DREAMseq trial in melanoma

Michael B Atkins

Clinical advances in hematology & oncology : H&Ono. 6 (2023): 304-306

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn